ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B
EDISON, N.J., Sept. 12, 2016 /PRNewswire/ -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it has taken a major step forward in its pursuit of a potentially curative combination therapy for chronic hepatitis B (HBV).